Inloggad som:
avslutad_Keynote-B21, GOG.3053
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
avslutad_Keynote-B21, GOG.3053
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
PLACEHOLDER
Randomisering mellan tillägg av Pembrolizumab/placeo i kombination med kurativ adjuvant behandling
Mer information om studien för vårdgivare
Studien ändrades senast av: studysonia (2023-05-15)